AllSci News
Sanford Burnham Prebys receives USD 3.86m NIH grant for NTR1 pain management program
Sanford Burnham Prebys Medical Discovery Institute has received a USD 3.86 million UG3 cooperative agreement from the National Institute of Neurological...
Yale University receives USD 1.38m NIH grant for CRISPR-based Alzheimer's tau therapy
Yale University has received a USD 1.38 million NIH cooperative agreement from the National Institute of Neurological Disorders and Stroke to develop a...
South Korea makes Curocell’s Rimqarto first CAR-T therapy to gain approval
South Korea’s Ministry of Food and Drug Safety has granted full regulatory approval to Rimqarto (anbalcabtagene autoleucel), making Curocell the first Korean…
FDA grants priority review to Jazz Pharmaceuticals' Ziihera for first-line HER2-positive gastric cancer
Jazz Pharmaceuticals submitted a supplemental Biologics License Application (sBLA) to the US FDA for Ziihera (zanidatamab-hrii) in combination regimens for...
Novo Nordisk's denecimig reduces hemophilia A bleeding rates by up to 99% in Phase III trial
Novo Nordisk's (Novo) investigational denecimig hemophilia A therapy reported Phase III data showing the bispecific antibody cut annualized bleeding rates...
BeOne Medicines secures USD 2.02b option on Huahui Health trispecific antibody HH160
Huahui Health grants BeOne Medicines a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A...
Organogenesis completes BLA submission for Renu for symptomatic knee osteoarthritis management
Organogenesis completed a rolling Biologics License Application (BLA) submission to the US FDA for Renu (cryopreserved amniotic suspension allograft),...
Calidi Bio partners with TransferAI on agentic AI for CLD-401 IND submission
Calidi Biotherapeutics (NYSE American: CLDI) has entered a collaboration with TransferAI, a private Austin-based AI company, to apply agentic AI...
AstraZeneca licenses Pinetree Therapeutics EGFR degrader program for USD 25m option exercise
AstraZeneca (NYSE: AZN) has exercised its option to license Pinetree Therapeutics' EGFR degrader program, converting a preclinical option agreement into a...
Veradermics to debut on NYSE for USD 384.4m to advance pattern hair loss therapeutic development
Veradermics (NYSE: Mane), a New Haven, Connecticut-based late clinical-stage biopharmaceutical company focused on pattern hair loss therapeutics, announced...
AstraZeneca's Q1'26 Earnings Call: Mixed messages for tozorakimab, efzimfotase alfa
AstraZeneca's Q1 2026 earnings conference call, held on April 29, 2026, was dominated by three converging pipeline signals: a historic triple Phase III...
Astellas Pivots Away from XTANDI, Betting Big on KRAS Degraders and Gene Therapy
Astellas Pharma's Q4 FY2025 earnings call, held April 27, 2026, revealed a company accelerating its transition away from XTANDI dependence through a...
AstraZeneca, Amgen participate in FDA pilot of real-time clinical trials
The US FDA announced on April 28 that it has successfully initiated two proof-of-concept studies designed to transmit trial endpoints and data signals to...
Boehringer Ingelheim's survodutide achieves 16.6% weight loss in Phase III obesity trial
Boehringer Ingelheim reported that survodutide, its investigational glucagon/GLP-1 dual agonist, produced an average body weight reduction of 16.6% over 76...
Zealand Pharma and Roche advance petrelintide into Phase III for chronic weight management
Zealand Pharma (Nasdaq: ZEAL) and Roche announced they will advance petrelintide into Phase 3 development for chronic weight management following Phase 2...
The AllSci Brief
Systematic R&D and deal news. Daily.